Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 24:27:e929558.
doi: 10.12659/MSM.929558.

Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer

Affiliations

Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer

Zexing Shan et al. Med Sci Monit. .

Abstract

BACKGROUND Gastric cancer is the most common gastrointestinal tumor, and the rates of recurrence and metastasis are high. Research results on molecular biomarkers used for prognosis of gastric cancer remain inconclusive. This study aimed to explore the gene expression module of gastric cancer and to determine potential prognostic biomarkers. MATERIAL AND METHODS Three microarray datasets (GSE13911, GSE79973, and GSE29272) from Gene Expression Omnibus (GEO), including 206 pairs of gastric tumors and adjacent normal samples, were used for analysis of differentially expressed genes (DEGs). The 3 microarray datasets yielded 144 genes associated with the progression and prognosis of gastric cancer. After this, a risk score model was developed for result validation using an independent dataset from The Cancer Genome Atlas. RESULTS The validation of the independent dataset showed significantly increased NID2, SPARC, and MFAP2 expression in gastric tumor tissues, which were associated with poor outcomes in gastric cancer patients. Moreover, the high risk score obtained was associated with poor overall survival (HR: 1.787; 1.069-2.986; P=0.027). Subgroup analyses revealed that these significant prognostic values were detected in patients aged <65.0 years, tumors in the antrum/distal colon, grade 3 tumors, or TNM-M0 stages of cancer. CONCLUSIONS The findings of this study show that NID2, SPARC, and MFAP2 are upregulated in gastric tumor tissues and are significantly associated with poor overall survival. Therefore, the predictive values of the risk score model employed for the prognosis of gastric cancer could be improved by using these 3 upregulated DEGs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

None.

Figures

Figure 1
Figure 1
The details regarding the expression data from primary gastric tumors and adjacent normal samples in 4 subsets of 3 datasets.
Figure 2
Figure 2
Identification of differentially expressed genes. Visualization of the identified differentially expressed genes was performed by volcano plots. Dots represent genes with color coding: red indicates upregulated, blue indicates downregulated, and black indicates genes that are not differentially expressed.
Figure 3
Figure 3
Venn diagram of the overlapping parts of the 4 subsets of 3 datasets of differentially expressed genes. Sixty-one genes were upregulated and 83 were downregulated.
Figure 4
Figure 4
Overall survival according to the expression of NID2, SPARC, and MFAP2. Red line indicates high expression and blue line indicates low expression.
Figure 5
Figure 5
Overall survival according to the risk scores after propensity score analysis. Red line indicates high risk score and blue line indicates low risk score.

Similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide:IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; [accessed on 06/018/2019]. http://globocan.iarc.fr.
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Information Committee of Korean Gastric Cancer Association. Korean Gastric Cancer Association Nationwide Survey on Gastric Cancer in 2014. J Gastric Cancer. 2016;16(3):131–40. - PMC - PubMed
    1. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : A phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. - PubMed
    1. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93. - PubMed

MeSH terms